Abstract
Introduction
Mepolizumab, a humanized anti IL-5 monoclonal antibody, has been used off-label for chronic eosinophilic pneumonia (CEP), inducing disease remission and saving systemic corticosteroids.
Case Study
We present a case of CEP, requiring long-term corticosteroids therapy due to relapse upon withdrawal. Mepolizumab was started and maintained for 2 years and 6 months.
Results
Corticosteroids could be withdrawn and mepolizumab dose interval was spared up to 10 wk with no disease relapse.
Conclusion
Mepolizumab is shown to be useful for chronic eosinophilic pneumonia, allowing corticosteroid withdrawal. Dose interval may be individualized under close monitoring, for a more efficient treatment, reducing medical costs while improving patients’ quality of life.
Declaration of interest
No potential conflict of interest was reported by the author(s).